Awards Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesLOS ANGELES, May 08, 2025 (GLOBE ...

TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to ...

Biogen’s partner, Japan-based Eisai, leads the clinical development and regulatory submissions for Leqembi. Though both companies co-commercialize and co-promote the drug, Eisai has the final ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

UK regulators are set to review a proposed label update for Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) Alzheimer’s drug ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

The tool, a collaboration with Eisai and Biogen , helps healthcare providers (HCPs), clinics, and infusion centers efficiently manage the care of patients undergoing treatment by tracking required ...

The tool, a collaboration with Eisai and Biogen, helps healthcare providers (HCPs), clinics, and infusion centers efficiently manage the care of patients undergoing treatment by tracking required ...